Vertex PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
By Sam Boughedda Vertex Pharma (NASDAQ:VRTX) was upgraded to Outperform from Market Perform by SVB Securities analysts who argue that the company's growth and durability are...
By Daniel Shvartsman Investing.com -- Entering the last trading day of the year, it's no surprise to find the 2022 scoreboard filled with energy winners and tech losers. The Dow...
Sales growth is a very important financial metric that investors consider before making a buy decision. By analyzing this key metric over a period of time, investors can easily get...
S&P 500 EPS growth for Q2 is set to come in at 6.0%, the lowest level since Q4 2020 Some highly anticipated names reported last week, with big EPS misses from big...
Inflation worries continue to weigh on equity markets Earnings season will likely increase volatility ETFs offer investors ability to diversify Earnings season has started with...
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.
| Average | 329.16 (+2.40% Upside) |
| High | 440.00 |
| Low | 280.00 |
| Price | 321.45 |
| No. of Analysts | 25 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 19.95 | 20.10 | 19.81 | -0.05 | -0.25% | 36.84M | NYSE | |||
| 145.93 | 147.23 | 143.08 | +1.97 | +1.37% | 70.26M | NASDAQ | |||
| 99.37 | 100.32 | 97.31 | +1.85 | +1.90% | 33.74M | NASDAQ | |||
| 177.88 | 180.68 | 161.17 | +17.61 | +10.99% | 304.01M | NASDAQ | |||
| 35.45 | 35.78 | 35.26 | +0.11 | +0.31% | 29.75M | NYSE | |||
| 28.16 | 28.24 | 26.78 | -1.93 | -6.41% | 147.99M | NASDAQ | |||
| 0.0649 | 0.0735 | 0.0645 | -0.0069 | -9.61% | 399.32M | NASDAQ | |||
| 41.56 | 41.78 | 41.37 | -0.04 | -0.10% | 910.97K | NYSE | |||
| 61.37 | 62.29 | 52.41 | +8.35 | +15.75% | 24.31M | NASDAQ | |||
| 48.51 | 48.73 | 47.97 | +0.17 | +0.35% | 13.34M | NASDAQ | |||
| 2.81 | 2.84 | 2.65 | +0.11 | +4.07% | 939.44K | NASDAQ | |||
| 13.27 | 13.36 | 12.87 | +0.35 | +2.71% | 61.75M | NYSE | |||
| 50.08 | 50.17 | 47.62 | +1.75 | +3.62% | 24.41M | NYSE | |||
| 7.96 | 8.14 | 7.93 | -0.23 | -2.81% | 5.98M | NYSE | |||
| 74.30 | 76.38 | 73.92 | -1.97 | -2.58% | 903.80K | NASDAQ |